Press Releases

Date Title  
Toggle Summary Audentes Therapeutics Announces Pricing of Initial Public Offering
SAN FRANCISCO, July 19, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc., a biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases, today announced the pricing of its initial public offering of
Toggle Summary Audentes Therapeutics and the University of Pennsylvania Announce Collaboration to Develop AAV Gene Therapy for Severe Liver Disease
IND filing for AT342 for the Treatment of Crigler-Najjar Syndrome Expected in 2016 and Preliminary Data from a Phase 1/2 Clinical Trial Expected in 2017 SAN FRANCISCO, CA – May 4, 2016  – Audentes Therapeutics, Inc., a biotechnology company focused on developing and commercializing gene
Toggle Summary Audentes Therapeutics Announces Presentation of Data at the American Society of Gene and Cell Therapy Annual Meeting
SAN FRANCISCO, CA – April 27, 2016  – Audentes Therapeutics, Inc., a biotechnology company focused on developing and commercializing gene therapy products for patients with serious, rare diseases, announced today that data related to its product candidate AT132 will be presented at the 19th
Toggle Summary Audentes Therapeutics Appoints Scott W. Morrison to Board of Directors
SAN FRANCISCO, CA   – January 5, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the appointment of Scott Morrison to its board of directors. Mr.
Toggle Summary Audentes Therapeutics Raises $65 Million In Series C Financing
Leading Healthcare Investors Provide Funding to Advance AAV Gene Therapy Pipeline in Serious, Rare Diseases to Key Clinical Milestones and to Build Internal Manufacturing Capabilities SAN FRANCISCO, CA – October 13, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the
Toggle Summary Audentes Therapeutics Expands Senior Leadership Team
Natalie Holles Appointed Chief Operating Officer, Thomas Soloway Appointed Chief Financial Officer and Kevin Baker, Ph.D. Appointed Senior Vice President, Preclinical Development SAN FRANCISCO, CA – September 29, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the
Toggle Summary Audentes Therapeutics Acquires Cardiac Gene Therapy Company Cardiogen Sciences
Audentes Expands Portfolio to Include AAV Gene Therapy for Rare, Genetic Cardiac Diseases including CASQ2-CPVT, an Inherited Arrhythmia with a High Risk of Mortality SAN FRANCISCO, CA – September 1, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and
Toggle Summary Audentes Therapeutics Receives Orphan Drug Designation for AT001 for the Treatment of X-Linked Myotubular Myopathy in the US and Europe
SAN FRANCISCO, CA – August 26, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced that AT001, an investigational product in development for the treatment of
Toggle Summary Audentes Therapeutics To Participate In 2015 Piper Jaffray Genomerx Symposium & 1×1 Day
SAN FRANCISCO, CA – May 14, 2014 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, and John T.
Toggle Summary Audentes Therapeutics Announces New Data To Be Presented At American Society Of Gene And Cell Therapy Annual Meeting
Compelling additional preclinical data further support therapeutic potential of gene therapy products to treat X-Linked Myotubular Myopathy and Pompe Disease SAN FRANCISCO, CA – May 11, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of